cas 76536-66-8|| where to buy 9,10-dimethoxy-2-[(2,4,6-trimethylphenyl)amino]-4H,6H,7H-pyrimido[4,3-a]isoquinolin-4-one

Nom du produit:9,10-dimethoxy-2-[(2,4,6-trimethylphenyl)amino]-4H,6H,7H-pyrimido[4,3-a]isoquinolin-4-one

IUPAC Name:9,10-dimethoxy-2-[(2,4,6-trimethylphenyl)amino]-4H,6H,7H-pyrimido[4,3-a]isoquinolin-4-one

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 76536-66-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:76536-66-8; Formule moléculaire:C23H25N3O3; Point de fusion:-; Code SMILES:COC1=CC2=C(C=C1OC)C1=CC(NC3=C(C)C=C(C)C=C3C)=NC(=O)N1CC2; Densité:

: Numéro de catalogue:CM1045836; Poids moléculaire:391.47; Point d'ébullition:; N° Mdl:; Stockage:

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Ensifentrine; Verona Pharma's Ensifentrine was accepted for NDA Review by FDA for chronic obstructive pulmonary disease (COPD) maintenance treatment. COPD is used to describe chronic lung diseases, encompassing emphysema, and chronic bronchitis. Phase 3 ENHANCE trials demonstrated Ensifentrine's efficacy and safety, showing significant improvements in lung function, symptom endpoints, and reducing the rate and risk of COPD exacerbations. Ensifentrine offers a novel mechanism of action. It is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4); it is also an activator of the cystic fibrosis transmembrane conductance regulator (CFTR).